Phase 2 trial of nivolumab and ramucirumab for relapsed mesothelioma: HCRN-LUN15-299 2023

Alliance Foundation Trial 09: a randomized, multicenter, phase 2 trial evaluating two sequences of pembrolizumab and standard platinum-based chemotherapy in patients with metastatic NSCLC 2021